ArticleHeliyon2024
Systematic review and meta-analysis of photon radiotherapy versus proton beam therapy for pediatric intracranial ependymoma: TRP-ependymoma 2024.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tracing the history of clinical practice of liquid biopsy: a bibliometric analysis.Frontiers in immunology · 2025Pooled it
- East Asian multi-centre study on clinical long-term outcomes of postoperative proton beam therapy for localised paediatric intracranial ependymoma.Clinical and translational radiation oncology · 2026Article
- Review
- Proton Beam Therapy for a Rare Anaplastic Pleomorphic Xanthoastrocytoma: Case Report and Literature Review.International journal of particle therapy · 2025Article
- Analysis of brain necrosis and secondary cancers after proton beam therapy for pediatric intracranial tumors: a single-center retrospective study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Proton beam therapy (PBT) may reduce the number of adverse events in treatment of patients with pediatric cancer. However, it is difficult to evaluate whether the actual therapeutic effect is truly equivalent to that of photon radiotherapy. To compare photon radiotherapy and PBT, a meta-analysis and systematic review were performed. Methods: The meta-analysis used papers from 1990 to 2023 in which postoperative local photon radiotherapy or PBT was performed for pediatric intracranial ependymomas. Fifteen articles (5 PBT, 9 photon radiotherapy, one both) were selected based on administration of radiotherapy as local irradiation. Results: Among the 15 chosen articles, the 1- to 5-year overall survival (OS) rates (photon radiotherapy vs. PBT) were 95.4 % (95 % confidence interval (CI) 92.8-97.1 %) vs. 97.2 % (95.7-98.2 %); 88.3 % (85.0-90.9 %) vs. 93.5 % (91.4-95.1 %); 81.2 % (76.9-84.8 %) vs. 91.1 % (88.4-93.2 %); 76.9 % (71.2-81.6 %) vs. 86.1 % (81.9-89.4 %); and 73.8 % (68.3-78.5 %) vs. 84.7 % (79.9-88.5 %), respectively. The 1- to 5-year local control (LC) rates (photon radiotherapy vs. PBT) were 90.9 % (95 % CI 83.9-94.9 %) vs. 91.0 % (88.7-92.9 %); 81.5 % (68.9-89.4 %) vs. 85.7 % (82.0-88.6 %); 77.3 % (62.8-86.8 %) vs. 82.6 % (79.1-85.5 %); 74.6 % (57.7-85.6 %) vs. 78.3 % (71.6-83.5 %); and 72.6 % (51.4-85.8 %) vs. 79.0 % (73.4-83.5 %), respectively. The meta-regression analysis identified relationships of modality (photon radiotherapy vs. PBT), age at irradiation, pathology (Grade 2 vs. Grade 3), and tumor removal (complete resection vs. none) with significantly better 3-year OS after PBT and better 1- to 5-year LC at a younger age. Conclusion: In postoperative local irradiation of ependymomas in children, proton beam therapy had outcomes comparable to those of photon radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.